Memantine Hydrochloride

[29 October 2015]

Products Affected - Description

Namenda XR oral capsule, Actavis (formerly Forest)
14 mg, unit-dose 100 count (NDC 00456-3414-63)
28 mg, 90 count (NDC 00456-3428-90)
28 mg, unit-dose 100 count (NDC 00456-3428-63)
Titration Pack 28 count (NDC 00456-3400-29)

Reason for the Shortage

  • Actavis (formerly Forest) states the reason for the shortage of Namenda XR capsules is manufacturing delay.
  • Actavis launched generic memantine immediate release tablets in July 2015. There are several other manufacturers of generic memantine immediate release tablets and supplies are available.

Available Products

Namenda XR oral capsule, Actavis (formerly Forest)
7 mg, 30 count (NDC 00456-3407-33)
14 mg, 30 count (NDC 00456-3414-33)
14 mg, 90 count (NDC 00456-3414-90)
21 mg, 30 count (NDC 00456-3421-33)
28 mg, 30 count (NDC 00456-3428-33)

Estimated Resupply Dates

Actavis has Namenda XR 14 mg and 28 mg 100 count unit-dose presentations and the titration packs temporarily unavailable and the company cannot estimate when product will return. Namenda XR 28 mg tablets in 90 count are on back order and the company cannot estimate a release date.

Related Shortages


October 29, August 6, 4 and 3, May 8, April 20, January 27 and 6, 2015; November 26 and 3, September 29 and 3, August 7, June 23, March 31, February 19, 2014, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.